Doctor profile · Federal record
Dr. Maged Hosny, MD
Rheumatology Physician (CMS: Rheumatology) · Dover, DE
- NPI 1326003351
- Accepts Medicare
- MIPS 99.0 / 100 · 2023
- 38 yrs in practice
- Male
- Solo practice
- No sanctions
Practice & contact
- Primary practice
-
260 Beiser Blvd Ste 201
Dover, DE 199047790
(302) 678-7438
fax (302) 678-7434 - Mailing address
-
Po Box 723
Milford, DE 199630763
Credentials & registration
- NPI registered
- April 2006 — 20 yrs on file
- Profile last updated
- March 19, 2014
- Year of graduation
- 1988 — 38 yrs since
- Specialty taxonomy
- 207RR0500X — NUCC code
- State license (1)
- Delaware #C10005894
- Medicaid
- DE #0001051001
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1326003351. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
274,338
Distinct HCPCS
10
Medicare allowed
$3,970,786
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J0717 |
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 169,200 | 42 | $5 | |
J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 28,075 | 57 | $41 | |
J1602 |
Injection, golimumab, 1 mg, for intravenous use | 27,332 | 32 | $12 | |
J0897 |
Injection, denosumab, 1 mg | 25,680 | 263 | $23 | |
Q5104 |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 11,410 | 48 | $38 | |
J1745 |
Injection, infliximab, excludes biosimilar, 10 mg | 4,270 | 24 | $32 | |
J7325 |
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | 2,528 | 22 | $9 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 1,358 | 892 | $88 | |
96413 |
Administration of chemotherapy into vein, 1 hour or less | 974 | 156 | $128 | |
96401 |
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 870 | 43 | $73 |
In context: peer comparison
Among 2 peers in Dover Rheumatology Physician, average services per provider: 8,888. This provider delivers 31× the peer median.Medicare Part D · 2023
Top prescriptions
Total claims
6,449
Patients
1,633
Total drug cost
$1,671,710
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Prednisone | Generic | 2,738 | 611 | $24,375 |
| Hydroxychloroquine Sulfate | Generic | 1,061 | 264 | $73,273 |
| Methotrexate (Methotrexate Sodium) | Brand | 752 | 188 | $25,604 |
| Alendronate Sodium | Generic | 257 | 109 | $3,899 |
| Duloxetine Hcl | Generic | 221 | 57 | $6,324 |
| Gabapentin | Generic | 210 | 48 | $6,230 |
| Meloxicam | Generic | 206 | 56 | $1,494 |
| Allopurinol | Generic | 197 | 62 | $2,879 |
| Humira(Cf) Pen (Adalimumab) | Brand | 180 | 21 | $1,503,070 |
| Cyclobenzaprine Hcl | Generic | 119 | 36 | $1,665 |
Hospital affiliations
Frequently asked questions
What is Dr. Maged Hosny's medical specialty?
Dr. Maged Hosny practices Rheumatology Physician in Dover, DE.
Where does Dr. Maged Hosny practice?
Dr. Maged Hosny practices at 260 Beiser Blvd Ste 201, Dover, DE 199047790. Office phone: 3026787438.
What is Dr. Maged Hosny's NPI?
Dr. Maged Hosny's National Provider Identifier (NPI) is 1326003351, issued by NPPES.
Does Dr. Maged Hosny accept Medicare assignment?
Yes. Dr. Maged Hosny accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Maged Hosny commonly perform?
Top Medicare-reported procedures in 2023: Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0717); Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS J0129); Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602). Source: CMS Medicare Physician & Other Practitioners file.